Mentioned On
Episode Mentions
The Top Line · Jul 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
“Obesity candidate focuses on visceral fat reduction and lean mass preservation versus current GLP-1 approaches”
Vertex Crinetics acquisition and rare endocrine disease expansionClinical trial regulation and China data integrity scrutinyGLP-1 agonist efficacy and weight loss outcomes
View Analysis
Pharma and BioTech Daily · May 13, 2026
Pfizer's $85M Breast Cancer Deal & FDA Shakeup | Pharma and Biotech Daily
“Invested €407M in Immunitas Therapeutics for first-in-class biologics in chronic inflammatory and autoimmune diseases”
FDA Leadership Transition and Regulatory StrategyPrecision Oncology and Targeted Breast Cancer TherapiesBiosimilar Competition and Market Erosion
View AnalysisPharma and BioTech Daily · Apr 29, 2026
AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily
“Phase 3 trial of dual agonist for weight loss showed 16% reduction, positioning as cardiometabolic risk reducer”
FDA Drug Approval and RescissionData Integrity in Drug DevelopmentAI-Designed Therapeutics
View Analysis